The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc.

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers.

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen ...

The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric and gastroesophageal junction cancer met all its efficacy objectives, with significant ...

Get the latest Zai Lab Limited (ZLAB) stock news and headlines to help you in your trading and investing decisions.

New data presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) highlight the robust performance of a tissue-free molecular residual disease (MRD) assay, Latitude, in ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high ...